Our monthly roundup of surveys and reports from around the industry. This month, children’s mental health, ACA proving a reduction in uninsured black Americans, and people are willing to open their data if it leads to a better experience.
Read More
The AMA announced an editorial update to Current Procedural Terminology, the nation’s leading medical terminology code set for describing health care procedures and services, that includes new product and administration codes assigned to the Pfizer-BioNTech COVID-19 vaccine for children 6 months to under 5 years of age.
The AMA announced the launch of a new developer program to help creators of health technology and services easily leverage AMA-published content from Current Procedural Terminology, the nation’s leading medical terminology for describing and coding health care procedures and services.
The American Medical Association announced an editorial update to the Current Procedural Terminology code set that includes a new vaccine administration code for a third dose of the pediatric COVID-19 vaccine developed by Pfizer.
As part of its commitment to eliminating inequities and improving access to care for historically marginalized communities across the nation, the AMA bolstered policy aimed at addressing the health needs of rural populations—enhancing access to care through educational strategies for rural physician workforce expansion.
Watch our continued value-based care series with panelists from the AMA discussing the current-state challenges of hypertension, the role of remote patient monitoring of blood pressure and define the return on investment at all levels.
The American Medical Association announced that the Current Procedural Terminology code set has been updated by the CPT Editorial Panel to include a new code for booster doses of COVID-19 vaccine created by Janssen Pharmaceutical Companies of Johnson & Johnson.
The AMA announced that the CPT® code set has been updated by the CPT Editorial Panel. The provisional CPT codes will be effective for use on the condition that Pfizer’s two-dose regimen for the prevention of COVID-19 in children ages 5 to 11 receives approval or emergency use authorization from the FDA.
The American Medical Association called the Biden Administration’s interim final rule on surprise billing an undeserved gift to the insurance industry that will reduce health care options for patients.